Loading
A phase 2/3 trial testing LAM561 in glioma & glioblastoma, active and no longer recruiting.
LAM561 With RT and TMZ for Adults With Glioblastoma is a phase 2/3 interventional study registered as NCT04250922, led by Laminar Pharmaceuticals with Laboratory of America, Northern Institute for Cancer Research, Newcastle and Theradis pharma, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment. Planned enrolment is 144 participants (actual). The study started in 2019-12-01 and primary completion is expected in 2026-01-15. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/